Explore

Trendline Trendline
Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026
Trendline Trendline
Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer to Drive Growth

Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer to Drive Growth

Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer to Drive Growth
Trendline Trendline
Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments
Trendline Trendline
Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects
Trendline Trendline
TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase
Trendline Trendline
Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development